Lipolysis

Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX

Retrieved on: 
Monday, April 8, 2024
Venus, Magnetic field, Communication, System, Spasm, Abdomen, History, Research, Human, Ministry of Health, Cellulite, Lipolysis, Annual report, Pain, Ministry, FDA

TORONTO, April 08, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received approval for the Venus Bliss MAX from the State of Israel Ministry of Health.

Key Points: 
  • TORONTO, April 08, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received approval for the Venus Bliss MAX from the State of Israel Ministry of Health.
  • The Venus Bliss MAX was first launched commercially in the United States in Q1 2022 after FDA 510(k) clearance and offered internationally in approved jurisdictions.
  • The Venus Bliss MAX offers three advanced technologies in one platform: diode laser applicators, (MP)2 applicator that combines Multi-Polar Radio Frequency and Pulsed Electro Magnetic Fields with advanced VariPulse™ technology and the Company’s FlexMax EMS applicators.
  • “The Venus Bliss MAX has been well received internationally, and we look forward to bringing our comprehensive all-in-one platform to the Israeli aesthetic service providers,” said Dr. Hemanth Varghese, President and Chief Operating Officer of Venus Concept.

Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 6, 2024
Therapy, Facial muscles, Pharmacology, Central nervous system, Research, GSK, MD, Liver disease, Dystrophin, Obesity, Cerebrospinal fluid, N-Acetylgalactosamine, HD, Weight loss, DMD, Duchenne muscular dystrophy, Lof, Exercise, Lipolysis, Exon, MBA, Conference, Wave, Activin and inhibin, AATD, Health, Safety, Biomarker, RNA, Greenshoe, Genetics, Pharmacokinetics, Webcast, Patient, Clinical trial, HTT, Q&A, Small RNA, Serum, Episcopal conference, Human, Coronary artery disease, Pharmaceutical industry

In the fourth quarter of 2023, Wave initiated dosing in RestorAATion-1, which resulted in a $20 million milestone payment from GSK.

Key Points: 
  • In the fourth quarter of 2023, Wave initiated dosing in RestorAATion-1, which resulted in a $20 million milestone payment from GSK.
  • Revenue was $29.1 million for the fourth quarter of 2023 as compared to $1.2 million in the prior year quarter.
  • Net loss was $16.3 million for the fourth quarter of 2023 as compared to $43.7 million in the prior year quarter.
  • ET to review the fourth quarter and full year 2023 financial results and pipeline updates.

Caliway Announced Orphan Drug Designation Granted to CBL-514 for the Treatment of Dercum's Disease

Retrieved on: 
Sunday, March 3, 2024
Lipoma, Marketing, FDA, Food, Pain, Connective tissue, Dercum's disease, Lipolysis, Apoptosis, ODD, Safety, Pharmaceutical industry

NEW TAIPEI CITY, March 3, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to CBL-514 for Dercum's disease treatment. CBL-514 is a lipolysis injection that can reduce local subcutaneous fat by inducing adipocyte apoptosis, and is the first drug to receive both ODD and Fast Track designation for Dercum's disease treatment.

Key Points: 
  • - CBL-514 is the first and only drug to receive both Orphan Drug Designation and Fast Track designation for Dercum's disease treatment.
  • NEW TAIPEI CITY, March 3, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to CBL-514 for Dercum's disease treatment.
  • CBL-514 is a lipolysis injection that can reduce local subcutaneous fat by inducing adipocyte apoptosis, and is the first drug to receive both ODD and Fast Track designation for Dercum's disease treatment.
  • "Receiving Orphan Drug Designation and Fast Track designation from the U.S. FDA is a huge milestone in CBL-514 development.

Caliway Received U.S. FDA Fast Track Designation for CBL-514 for the Treatment of Dercum's Disease

Retrieved on: 
Thursday, February 15, 2024
Fast Track, Collection, Physician, FDA, Food, Pain, Connective tissue, Growth, U.S. FDA, Dercum's disease, Lipolysis, Apoptosis, Microsoft Access, Patient, Clinical trial, Disease, EAP, Trial of the century, Pharmaceutical industry

NEW TAIPEI CITY, Feb. 14, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of CBL-514 in Dercum's disease treatment. CBL-514 is a lipolysis injection that can reduce local subcutaneous fat by selectively inducing adipocyte apoptosis, and is the first drug to receive Fast Track designation for Dercum's disease treatment.

Key Points: 
  • - CBL-514 is the first drug to receive Fast Track designation for Dercum's disease treatment.
  • NEW TAIPEI CITY, Feb. 14, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of CBL-514 in Dercum's disease treatment.
  • "We are very pleased to see the FDA's decision on granting Fast Track designation to CBL-514," said Vivian Ling, CEO of Caliway.
  • The Expanded Access Program is a program recognized by the FDA as a follow-on to their Fast Track Designation.

Medical Billing Outsourcing Market size to grow by USD 11,704.49 million from 2022 to 2027; The improvement in healthcare administrative processes, optimization, and operational efficiency will drive the market growth - Technavio

Retrieved on: 
Friday, June 9, 2023
HCLTech, Medicine, Medicaid, Epic Systems Corp. v. Lewis, EMR, Software, RCM, Quest Diagnostics, Reliability-centered maintenance, Electronic health record, HIT, USD, Experian, Medicare, Oracle Corporation, ONC, Patient, EHR, Risk, Genpact, Lipolysis, Growth, Health Information Technology for Economic and Clinical Health Act, McKesson Corporation, Federation, Geography, Pharmaceutical industry, Health insurance, COVID-19, L.L.C

Key players dominating the market have noteworthy shares in the global medical billing outsourcing market.

Key Points: 
  • Key players dominating the market have noteworthy shares in the global medical billing outsourcing market.
  • AdvancedMD Inc.: The company offers solutions for medical billing outsourcing for higher claims acceptance, faster reimbursements, and more revenue.
  • The report provides actionable insights and estimates the contribution of all regions to the growth of the global medical billing outsourcing market.
  • Complexities associated with the deployment of medical billing outsourcing services are one of the major challenges hampering the market growth.

Cutera® Celebrates 25 Years of Excellence in Innovation

Retrieved on: 
Friday, April 14, 2023
General Health, Surgery, Medical Devices, Health, Health Technology, Hair removal, Interim, Acne, FAAD, Dermatology, Patient, Engineering, Lipolysis, FDA, Imagination, Society, Medical imaging, MD

Cutera continues to establish a long legacy of imagination and engineering, developing novel technologies that have positively impacted practitioners and their patients worldwide.

Key Points: 
  • Cutera continues to establish a long legacy of imagination and engineering, developing novel technologies that have positively impacted practitioners and their patients worldwide.
  • Since its launch, AviClear has amassed multiple accolades including being named the “Best Laser Acne Treatment” by NewBeauty Magazine in April 2023.
  • “I am proud to work alongside a company who values our clinical input and keeps striving to improve their technology.
  • We are constantly impressed by their unique and creative approach to addressing challenging conditions, and their latest device, AviClear, is no exception.

OSANO Debuts Latest Products at COSMOPROF 2023

Retrieved on: 
Tuesday, March 14, 2023
LLLT, Lipolysis, LM, Skin, Abdomen, Osano, Cell, Patient, Lymphatic system, Safety, Pain, Acupuncture, Metabolism, Apoptosis, Medical imaging

BOLOGNA, Italy, March 14, 2023 /PRNewswire/ -- COSMOPROF WORLDWIDE BOLOGNA, one of the most influential global events dedicated to all facets of the beauty industry, is taking place from the 17th to 20th, March, 2023.

Key Points: 
  • BOLOGNA, Italy, March 14, 2023 /PRNewswire/ -- COSMOPROF WORLDWIDE BOLOGNA, one of the most influential global events dedicated to all facets of the beauty industry, is taking place from the 17th to 20th, March, 2023.
  • OSANO launched a series of top-notch products, including Beauty Equipment, Body Shaping Machine, Facial Care Machine, Ultrasound Cavitation Device, Lipo Laser Instrument, Hair Removal Machine, etc.
  • "We are thrilled to launch the latest products at the biggest beauty event in the world.
  • Cosmoprof 2023 offers the perfect platform to introduce cutting-edge technology, and we firmly believe that our products will attract attention from millions of beauty-trend lovers from all around the world," said Fusong Xu, Founder & CEO of OSANO.

Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates

Retrieved on: 
Monday, November 14, 2022
LUMO, Clinical trial, Non-alcoholic fatty liver disease, Liver disease, Pandemic, Safety, Disease, AHV, Growth, Fatty liver disease, Optimism, NEA, Massachusetts General Hospital, Lipolysis, Drug development, Eli Lilly, Inflammation, GH, FDA, NASH, Interim, PEM, Data, Therapy, UCB, Transgender hormone therapy, Pulsatile insulin, Fibrosis, Quarter, New Enterprise Associates, MGH, PD, Growth hormone, Risk, Degenerative disease, Research, Orphan, Patient, Pharmaceutical industry, Dietary supplement, EU, Lumos, NAFLD

AUSTIN, Texas, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that interim results met expectations for its Phase 2 OraGrowtH210 Trial and Phase 2 Pharmacokinetic/Pharmacodynamic (PK/PD) OraGrowtH212 Trial evaluating oral LUM-201 for subjects with moderate (idiopathic) pediatric growth hormone deficiency (PGHD) who screened PEM-positive utilizing Lumos’s predictive enrichment marker (PEM) strategy. Lumos also announced its financial results for the quarter ended September 30, 2022.

Key Points: 
  • Lumos also announced its financial results for the quarter ended September 30, 2022.
  • The Company expects cash use of approximately $8.5 to $9.5 million in the fourth quarter of 2022.
  • Lumos Pharma ended the third quarter 2022 with 8,375,271 shares outstanding.
  • Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases.

Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates

Retrieved on: 
Tuesday, August 9, 2022
Lipolysis, Injection, CEO, GLOBE, SEC, Clinical trial, Patient, Disease, UCB, Transgender hormone therapy, Growth hormone, Inflammation, Enrichment, Fibrosis, Data, Safety, LUMO, Orphan, Fatty liver disease, Computer-Assisted Passenger Prescreening System, Webcast, NEA, AHV, Interim, Growth, PEM, Massachusetts General Hospital, Optimism, NASH, Degenerative disease, Drug development, Pulsatile insulin, Liver disease, FDA, New Enterprise Associates, Private Securities Litigation Reform Act, Population, Non-alcoholic fatty liver disease, PD, GH, MGH, Company, Therapy, Risk, NASDAQ, Research, Adult, Fine chemical, Pharmaceutical industry, Dietary supplement, Medical imaging, Public relations, EU, NAFLD

AUSTIN, Texas, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced financial results for the quarter ended June 30, 2022.

Key Points: 
  • AUSTIN, Texas, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced financial results for the quarter ended June 30, 2022.
  • Financial Results for the Quarter Ended June 30, 2022
    Cash Position Lumos Pharma ended the quarter on June 30, 2022 with cash and cash equivalents totaling $79.5 million compared to $94.8 million on December 31, 2021.
  • Lumos Pharma ended the second quarter 2022 with 8,377,567 shares outstanding.
  • Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases.

$63.5 Billion Worldwide Human Insulin Industry to 2027 - Featuring Biocon, Novo Nordisk, Pfizer and SEDICO Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 14, 2022
Health, Pharmaceutical, Prevalence, Infection, Injury, Biotechnology, Glucose, Proteolysis, Escherichia, Diabetes, R, Globe, COVID-19, Insulin, HI, Needle, Laboratory, Blood, Lipolysis, Therapy, Liver, Human, Research, Growth, Obesity, Industry, Efficiency, Escherichia coli, Pharmaceutical industry, Vaccine, Potash, Sex industry

Human insulin (HI) is a form of synthetic insulin that is synthesized in laboratories for pharmaceutical use.

Key Points: 
  • Human insulin (HI) is a form of synthetic insulin that is synthesized in laboratories for pharmaceutical use.
  • It is bio-engineered by growing insulin proteins within E-coli bacteria (Escherichia coli) cells to mimic the properties of insulin naturally present in humans.
  • Key Questions Answered in This Report:
    How has the global human insulin market performed so far and how will it perform in the coming years?
  • What is the structure of the global human insulin market and who are the key players?